192 related articles for article (PubMed ID: 30787627)
1. Canagliflozin review - safety and efficacy profile in patients with T2DM.
Jakher H; Chang TI; Tan M; Mahaffey KW
Diabetes Metab Syndr Obes; 2019; 12():209-215. PubMed ID: 30787627
[TBL] [Abstract][Full Text] [Related]
2. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Neal B; Perkovic V; Mahaffey KW; de Zeeuw D; Fulcher G; Erondu N; Shaw W; Law G; Desai M; Matthews DR;
N Engl J Med; 2017 Aug; 377(7):644-657. PubMed ID: 28605608
[TBL] [Abstract][Full Text] [Related]
3. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.
Perkovic V; de Zeeuw D; Mahaffey KW; Fulcher G; Erondu N; Shaw W; Barrett TD; Weidner-Wells M; Deng H; Matthews DR; Neal B
Lancet Diabetes Endocrinol; 2018 Sep; 6(9):691-704. PubMed ID: 29937267
[TBL] [Abstract][Full Text] [Related]
4. Canagliflozin and cardiovascular and renal events in type 2 diabetes.
Guthrie R
Postgrad Med; 2018 Mar; 130(2):149-153. PubMed ID: 29297732
[TBL] [Abstract][Full Text] [Related]
5. The kidney and cardiovascular outcome trials.
Bloomgarden Z
J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
[TBL] [Abstract][Full Text] [Related]
6. The effects of canagliflozin in type 2 diabetes in subgroups defined by population-specific body mass index: Insights from the CANVAS Program and CREDENCE trial.
Yu J; Sweeting AN; Gianacas C; Houston L; Lee V; Fletcher RA; Perkovic V; Li Q; Neuen BL; Berwanger O; Heerspink HJL; de Zeeuw D; Arnott C
Diabetes Obes Metab; 2023 Dec; 25(12):3724-3735. PubMed ID: 37671609
[TBL] [Abstract][Full Text] [Related]
7. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).
Mahaffey KW; Neal B; Perkovic V; de Zeeuw D; Fulcher G; Erondu N; Shaw W; Fabbrini E; Sun T; Li Q; Desai M; Matthews DR;
Circulation; 2018 Jan; 137(4):323-334. PubMed ID: 29133604
[TBL] [Abstract][Full Text] [Related]
8. The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus.
Carbone S; Dixon DL
Cardiovasc Diabetol; 2019 May; 18(1):64. PubMed ID: 31138195
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function.
Neuen BL; Ohkuma T; Neal B; Matthews DR; de Zeeuw D; Mahaffey KW; Fulcher G; Desai M; Li Q; Deng H; Rosenthal N; Jardine MJ; Bakris G; Perkovic V
Circulation; 2018 Oct; 138(15):1537-1550. PubMed ID: 29941478
[TBL] [Abstract][Full Text] [Related]
10. [Canaglifozin results in cardiovascular and renal protection in patients with type 2 diabetes : from CANVAS to CREDENCE].
Scheen AJ
Rev Med Liege; 2019 Oct; 74(10):508-513. PubMed ID: 31609553
[TBL] [Abstract][Full Text] [Related]
11. Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program.
Neuen BL; Ohkuma T; Neal B; Matthews DR; de Zeeuw D; Mahaffey KW; Fulcher G; Li Q; Jardine M; Oh R; Heerspink HL; Perkovic V
J Am Soc Nephrol; 2019 Nov; 30(11):2229-2242. PubMed ID: 31530577
[TBL] [Abstract][Full Text] [Related]
12. Canagliflozin and Cardiovascular disease- results of the CANVAS trial.
Shah SR; Najim NI; Abbasi Z; Fatima M; Jangda AA; Shahnawaz W; Shahid M; Shah SA
J Community Hosp Intern Med Perspect; 2018; 8(5):267-268. PubMed ID: 30357039
[TBL] [Abstract][Full Text] [Related]
13. Treatment effect of canagliflozin for patients on therapy for heart failure: Pooled analysis of the CANVAS program and CREDENCE trial.
Jain SS; Yu J; Arnott C; Neal B; Perkovic V; Neuen BL; Jardine M; Mahaffey KW
Int J Cardiol; 2024 Jan; 395():131444. PubMed ID: 37844669
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program.
Yu J; Arnott C; Neuen BL; Heersprink HL; Mahaffey KW; Cannon CP; Khan SS; Baldridge AS; Shah SJ; Huang Y; Li C; Figtree GA; Perkovic V; Jardine MJ; Neal B; Huffman MD
ESC Heart Fail; 2021 Apr; 8(2):1482-1493. PubMed ID: 33595905
[TBL] [Abstract][Full Text] [Related]
15. Update on SGLT2 Inhibitors-New Data Released at the American Diabetes Association.
Lee S
Crit Pathw Cardiol; 2017 Sep; 16(3):93-95. PubMed ID: 28742644
[TBL] [Abstract][Full Text] [Related]
16. Kidney protection with canagliflozin: A combined analysis of the randomized CANVAS program and CREDENCE trials.
Sridhar VS; Neuen BL; Fletcher RA; Slee A; Ang FG; Rapattoni W; Arnott C; Cherney DZ; Perkovic V; Wheeler DC; Levin A
Diabetes Obes Metab; 2023 Aug; 25(8):2331-2339. PubMed ID: 37184050
[TBL] [Abstract][Full Text] [Related]
17. [Outcome studies on SGLT-2 inhibitors].
Seufert J; Laubner K
Internist (Berl); 2019 Sep; 60(9):903-911. PubMed ID: 31375850
[TBL] [Abstract][Full Text] [Related]
18. Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan: what was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan?
Fernandez-Fernandez B; Fernandez-Prado R; Górriz JL; Martinez-Castelao A; Navarro-González JF; Porrini E; Soler MJ; Ortiz A
Clin Kidney J; 2019 Jun; 12(3):313-321. PubMed ID: 31198532
[TBL] [Abstract][Full Text] [Related]
19. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
[TBL] [Abstract][Full Text] [Related]
20. Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS programme and CREDENCE trial.
Yu J; Li J; Leaver PJ; Arnott C; Huffman MD; Udell JA; Perkovic V; Mahaffey KW; de Zeeuw D; Fulcher G; Matthews DR; Shaw W; Rosenthal N; Neal B; Figtree GA
Cardiovasc Res; 2022 Mar; 118(4):1103-1114. PubMed ID: 33826709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]